Maier, S.; Tebartz van Elst, L.; Philipsen, A.; Lange, T.; Feige, B.; Glauche, V.; Nickel, K.; Matthies, S.; Alm, B.; Sobanski, E.;
et al. Effects of 12-Week Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The First Double-Blind Placebo-Controlled MR Spectroscopy Study. J. Clin. Med. 2020, 9, 2601.
https://doi.org/10.3390/jcm9082601
AMA Style
Maier S, Tebartz van Elst L, Philipsen A, Lange T, Feige B, Glauche V, Nickel K, Matthies S, Alm B, Sobanski E,
et al. Effects of 12-Week Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The First Double-Blind Placebo-Controlled MR Spectroscopy Study. Journal of Clinical Medicine. 2020; 9(8):2601.
https://doi.org/10.3390/jcm9082601
Chicago/Turabian Style
Maier, Simon, Ludger Tebartz van Elst, Alexandra Philipsen, Thomas Lange, Bernd Feige, Volkmar Glauche, Kathrin Nickel, Swantje Matthies, Barbara Alm, Esther Sobanski,
and et al. 2020. "Effects of 12-Week Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The First Double-Blind Placebo-Controlled MR Spectroscopy Study" Journal of Clinical Medicine 9, no. 8: 2601.
https://doi.org/10.3390/jcm9082601
APA Style
Maier, S., Tebartz van Elst, L., Philipsen, A., Lange, T., Feige, B., Glauche, V., Nickel, K., Matthies, S., Alm, B., Sobanski, E., Domschke, K., Perlov, E., & Endres, D.
(2020). Effects of 12-Week Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The First Double-Blind Placebo-Controlled MR Spectroscopy Study. Journal of Clinical Medicine, 9(8), 2601.
https://doi.org/10.3390/jcm9082601
